ES SUMMIT: Therapeutic Milestones In Parkinson’s Disease

VENICE, ITALY
MARCH 18-20, 2020

Program-at-a-Glance
Wednesday, March 18, 2020

1201 Parallel Session

Disease Modifying Therapies
14:00 – 16:00

Chairs: Filip Scheperjans, Finland
        Klaus Seppi, Austria

14:00 Drug Repurposing
        Alan Whone, United Kingdom

14:30 Neuroprotection by Conservative Iron Chelation
        David Devos, France

15:00 Clinical Trials Targeting Alpha-synuclein
        Anthony Lang, Canada

15:30 The Benefits of Nutritional Care in Parkinson’s Disease: Evidence and Potential
        Emanuele Cereda, Italy

ESPC Liaison: Caroline Moreau, France

At the conclusion of this session, participants should be better able to:
1. Examine the concept of drug repurposing, and how this may uncover new therapies for Parkinson’s disease patients.
2. Identify the role of iron in Parkinson’s disease and apprehend the concept of conservative chelation.
3. Discuss the challenges of targeting alpha-synuclein in clinical trials and where we are currently with such trials.
4. Describe how the progression of Parkinson’s disease might be slowed with non-pharmacological interventions such as physical exercise and dietary modifications.

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Students/Residents/Trainees

1202 Parallel Session

Diagnosis and Treatment of Autonomic Dysfunction and Sleep Disorders in Parkinson’s Disease
14:00 – 16:00

Chairs: Cristian G. Falup-Pecurariu, Romania
        Paolo Barone, Italy

14:00 Gastrointestinal Dysfunction
        Cristian G. Falup-Pecurariu, Romania

14:30 Urogenital Dysfunction
        Pietro Cortelli, Italy

15:00 Orthostatic Hypotension
        Roland Thijs, Netherlands

15:30 Sleep Disorders
        Alejandro Iranzo, Spain

ESPC Liaison: Cristian Falup-Pecurariu, Romania

At the conclusion of this session, participants should be better able to:
1. Summarize the different autonomic symptoms in Parkinson’s disease.
2. Evaluate the different pharmacological and surgical options for management of urogenital dysfunction in Parkinson’s disease.
3. Recognize the range of non-pharmacological treatment options for orthostatic hypotension in Parkinson’s disease.
4. Examine the different therapeutic strategies for management of sleep disorders in Parkinson’s disease.

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees
**Wednesday, March 18, 2020**

### Parallel Session

**1203  Parallel Session**

**Advanced Treatments in Parkinson's Disease**

**14:00 – 16:00**

**Chairs:** Jens Volkmann, *Germany*
Per Odin, *Sweden*

- **14:00** *Strategies to Optimize the Management of Complex Response Fluctuations*
  K. Ray Chaudhuri, *United Kingdom*
- **14:30** *When to Consider Patients for Invasive Therapies*
  Tove Henriksen, *Denmark*
- **15:00** Levodopa Infusion
  Pille Taba, *Estonia*
- **15:30** Apomorphine Infusion
  Regina Katzenschlager, *Austria*

**ESPC Liaison:** Angelo Antonini, *Italy*

At the conclusion of this session, participants should be better able to:
1. Understand the strategies to optimize the management of complex response fluctuations
2. Recognize when more invasive therapies for the management of advanced Parkinson's disease should be considered
3. Explain the risks and benefits of levodopa infusion therapies
4. Examine the risks and benefits of apomorphine infusion therapies

**Recommended Audience:** Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

### Plenary Session

**1204  Plenary Session**

**Opening Plenary Session**

**18:00 – 20:00**

**Chairs:** Bastiaan R. Bloem, *Netherlands*
Angelo Antonini, *Italy*

- **18:00** Welcome Remarks
  Claudia Trenkwalder, *MDS President*
  Angelo Antonini, *MDS-ES Section Chair*
  Elena Moro, *European Academy of Neurology Board Member*
- **18:15** The Voice of the Patient
  Omotola Thomas, *United Kingdom*
- **18:30** History of Treatments for Parkinson's Disease
  Werner Poewe, *Austria*
- **19:00** Basic Science Talk: Is Alpha-synuclein Really the Prime Target for Disease Modifying Therapies in Parkinson's Disease?
  Jeffrey Kordower, *USA*
- **19:30** Applied Science Talk: Multidisciplinary Care for Parkinson Patients: Models and Evidence
  Carsten Eggers, *Germany*

**ESPC Liaison:** Bastiaan Bloem, *Netherlands*

At the conclusion of this session, participants should be better able to:
1. Recognize what really matters to persons living with Parkinson's disease
2. Appraise what we have learned about Parkinson's disease in the past 203 years
3. Evaluate the rationale for tackling alpha-synuclein accumulation as possible disease-modifying treatment for Parkinson's disease patients
4. Discuss the evidence for the different models of multidisciplinary care for patients with Parkinson's disease

**Recommended Audience:** Basic Scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
### 2101 Plenary Session

**Palliative Care for Parkinson's Disease**  
8:00 – 9:30

**Chairs:**  
Carsten Eggers, *Germany*  
Anette Schrag, *United Kingdom*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Why? Joaquim J. Ferreira</td>
<td>Portugal</td>
</tr>
<tr>
<td>8:22</td>
<td>When? Marieke Groot</td>
<td>Netherlands</td>
</tr>
<tr>
<td>8:44</td>
<td>How? Stefan Lorenzl</td>
<td>Germany</td>
</tr>
<tr>
<td>9:06</td>
<td>Assessment of Outcomes Pablo Martinez-Martín</td>
<td>Spain</td>
</tr>
</tbody>
</table>

ESPC Liaison: Angelo Antonini, *Italy*

At the conclusion of this session, participants should be better able to:
1. Describe the unmet palliative care needs in the various stages of Parkinson's disease  
2. Identify the indications for palliative care management in patients with Parkinson's disease  
3. Discuss the various palliative interventions that are available for Parkinson's disease patients, including their evidence basis  
4. Recognize the challenges in measuring the outcome of palliative care interventions, including the need to develop new scales

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

### 2102 Plenary Session

**Technology in Parkinson's Disease: A New Era of Digital Help for Treatment Precision**  
10:00 – 12:00

**Chairs:**  
Jochen Klucken, *Germany*  
Timothy Lynch, *Ireland*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Telemedicine: Bringing Parkinson's Disease Care Back into the Patient's Home Jochen Klucken</td>
<td>Germany</td>
</tr>
<tr>
<td>10:30</td>
<td>Body-Worn Sensors: Options, Challenges and Evidence Anat Mirelman</td>
<td>Israel</td>
</tr>
<tr>
<td>11:00</td>
<td>Other Technological Applications Nienke M. de Vries</td>
<td>Netherlands</td>
</tr>
</tbody>
</table>
| 11:30 | Controversy: The Future of Outcome Assessments in Parkinson's Disease  
Digital Endpoints Lynn Rochester | United Kingdom |

ESPC Liaison: Bart Post, *Netherlands*

At the conclusion of this session, participants should be better able to:
1. Discuss the range of opportunities for use of technological advances in Parkinson's disease  
2. Identify barriers and facilitators for the implementation of technology in both daily practice and clinical research  
3. Review the evidence basis for the use of technology in Parkinson's disease  
4. Examine the challenges and new developments around outcome assessments

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Thursday, March 19, 2020

2100  Meet the Expert Sessions

12:00 – 13:00

These sessions will be in an interactive roundtable format and are meant to answer delegates’ questions and to provide them with practical knowledge on how to be successful in their careers. Smaller groups of 15-20 delegates will attend the session to facilitate a fruitful discussion. Each Expert will hold their discussion in a private conference room during this time.

If you would like to attend a Meet the Expert session please sign up during the Summit registration process. Please note that there is an additional fee to attend a Meet the Expert session.

Experts:
Claudia Trenkwalder, Germany and Marie Vidailhet, France
Murat Emre, Turkey and Nir Giladi, Israel
Peter Jenner, United Kingdom and Wolfgang Oertel, Germany

2203  Parallel Session

Diagnosis and Treatment of Axial Disability in Parkinson’s Disease
14:30 – 16:30

Chairs:  Caroline Moreau, France
        Murat Emre, Turkey

14:30  Clinical Manifestations of Axial Disability in Parkinson’s Disease: a Video Account
       Alice Nieuwboer, Belgium

15:00  Diagnosis and Management of Postural Deformities
       Karen M. Doherty, United Kingdom

15:30  Diagnosis and Management of Gait Difficulties
       Michele Tinazzi, Italy

16:00  Diagnosis and Management of Dysarthria and Dysphagia
       Caroline Moreau, France

ESPC Liaison: Bart Post, Netherlands

At the conclusion of this session, participants should be better able to:
1. Describe the rich spectrum of clinical manifestations of axial motor problems in patients with Parkinson’s disease
2. Recognize the presentation, impact and management of postural deformities in Parkinson’s disease
3. Explain the presentation, impact, and management of gait problems in Parkinson’s disease
4. Evaluate the impact and management of speech and swallowing difficulties in Parkinson’s disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Students/Residents/Trainees
Thursday, March 19, 2020

2204 Parallel Session

New Treatments for Parkinson's Disease
14:30 – 16:30

Chairs: Fabrizio Stocchi, Italy
Regina Katzenschlager, Austria

14:30 How to Design a Trial in the Clinical and Prodromal Phase
Camille Carroll, United Kingdom

14:55 Symptomatic Drugs: What is in the Pipeline for Parkinson's Disease?
Fabrizio Stocchi, Italy

15:20 Therapeutic Approaches for Genetic Forms of Parkinsonism
Jan Aasly, Norway

15:45 Stem Cells
Agnete Kirkeby, Sweden

16:10 Side Effects of Novel Therapies and Learning From Them
Emma Lane, United Kingdom

ESPC Liaison: Daniela Berg, Germany

At the conclusion of this session, participants should be better able to:
1. Recognize challenges of the clinical trial design in the clinical and prodromal phase of Parkinson's disease
2. Examine new drugs in development as possible disease-modifying treatment of Parkinson's disease
3. Describe the current knowledge about genetic form of parkinsonism and their possible treatment
4. Identify new drugs in development for the symptomatic treatment of Parkinson's disease

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

Determinants and Mechanisms of Progression of Parkinson's Disease: The Basis for New Treatments
14:30 – 16:30

Chairs: Miryam Carecchio, Italy
Stephane Lehericy, France

14:30 The Preclinical Phase of Parkinson's Disease
Heinz Reichmann, Germany

15:00 Clinical Predictors for Progression in Parkinson's Disease
Bart Post, Netherlands

15:30 Mechanisms Involved in Disease Progression
Tiago Outeiro, Germany

16:00 Imaging Biomarkers of Disease Progression
Per Borghammer, Denmark

ESPC Liaison: Miryam Carecchio, Italy

At the conclusion of this session, participants should be better able to:
1. Recognize the clinical features of the preclinical phase of Parkinson's disease
2. Identify the clinical factors that can predict progression in Parkinson's disease
3. Analyze the various mechanisms that contribute to disease progression in Parkinson's disease, including the role of inflammation and co-pathologies
4. Identify how new imaging techniques can help to understand the progression of Parkinson's disease

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Students/Residents/Trainees
**Thursday, March 19, 2020**

### 2206 Parallel Session

**The Role of Neurophysiology in Parkinson’s Disease Treatment**
*17:00 – 19:00*

**Chairs:** Walter Paulus, Germany  
John Rothwell, United Kingdom

- **17:00** Update in Transcranial Direct Current Stimulation (tDCS) in Parkinson’s Disease  
  David Benninger, Switzerland
- **17:30** Basal Ganglia Recordings  
  Alberto Priori, Italy
- **18:00** Repetitive Transcranial Magnetic Stimulation in Parkinson’s Disease  
  John Rothwell, United Kingdom
- **18:30** EEG and MEG in Parkinson’s Disease  
  Laura Bonanni, Italy

**ESPC Liaison:** Cristian Falup-Pecurariu, Romania

At the conclusion of this session, participants should be better able to:
1. Identify mechanisms of prehabilitation, priming the brain for physiotherapy by prior transcranial direct current stimulation or transcranial magnetic stimulation in Parkinson’s disease
2. Describe the mechanisms and implications of basal ganglia in Parkinson's disease
3. Examine repetitive transcranial magnetic stimulation (rTMS) in Parkinson's disease, recognize the main targets of stimulation and list the current efforts of novel stimulation parameters
4. Discuss the role of Electroencephalogram (EEG) and Magnetoencephalography (MEG) in Parkinson's disease

**Recommended Audience:** Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

### 2207 Parallel Session

**Promising Avenues for Personalized Gait Rehabilitation in Parkinson’s Disease**
*17:00 – 19:00*

**Chairs:** Alice Nieuwboer, Belgium  
Jorik Nonnekes, Netherlands

- **17:00** Adaptive Strategies for Gait Disorders in Parkinson’s Disease  
  Jorik Nonnekes, Netherlands
- **17:40** Is There a Role for Personalized Rehabilitation of Gait Impairment in Parkinson’s Disease?  
  Moran Gilat, Belgium
- **18:20** Technology to Measure and Promote Personalized Physical Activity Interventions in Parkinson’s Disease  
  Andrea Pilotto, Italy

**ESPC Liaison:** Joaquim Ferreira, Portugal

At the conclusion of this session, participants should be better able to:
1. Recognize the different types of gait problems in Parkinson's disease and how they may guide the different treatment options
2. Describe the concept of personalized medicine applied to treatment of gait impairment in Parkinson’s disease
3. Define how wearable sensors and other technological advances can be engaged in the personalized rehabilitation of gait disorders

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners
Thursday, March 19, 2020

2208  Parallel Session

The Genetics of Parkinson’s Disease
17:00 – 19:00

Chairs:  Enza Maria Valente, Italy
Thomas Gasser, Germany

17:00  Parkinson’s Disease Genetics: What is New?
Vincenzo Bonifati, Netherlands

17:30  Genotype-Phenotype Correlations In Genetic Early-Onset Parkinson's Disease
Enza Maria Valente, Italy

18:00  The Role of GBA in Parkinson’s Disease Pathogenesis: Basic and Treatment Implications
Anthony Schapira, United Kingdom

18:30  The Role of LRRK2 in Parkinson’s Disease Pathogenesis: Basic and Treatment Implications
Nir Giladi, Israel

ESPC Liaison: Miryam Carecchio, Italy

At the conclusion of this session, participants should be better able to:
1. Examine the range of recently discovered genetic factors in Parkinson’s disease
2. Discuss the range of clinical phenotypes associated with common genetic causes of parkinsonism
3. Describe the pathogenetic and clinical implications of GBA mutations in Parkinson’s disease
4. Recognize the pathogenetic and clinical implications of LRRK2 mutations in Parkinson’s disease

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

Friday, March 20, 2020

3100  Meet the Expert Sessions

7:00 – 8:00

These sessions will be in an interactive roundtable format and are meant to answer delegates’ questions and to provide them with practical knowledge on how to be successful in their careers. Smaller groups of 15-20 delegates will attend the session to facilitate a fruitful discussion. Each Expert will hold their discussion in a private conference room during this time.

If you would like to attend a Meet the Expert session please sign up during the Summit registration process. Please note that there is an additional fee to attend a Meet the Expert session.

Experts:  Günther Deuschl, Germany
Jose Obeso, Spain
Friday, March 20, 2020

3101 Plenary Session

New Advances in Surgical Treatments for Parkinson's Disease
8:00 – 9:30
Chairs: Jose Obeso, Spain
        Patricia Limousin, United Kingdom

8:00 Present and Future of Traditional Deep Brain Stimulation in Parkinson's Disease
        Elena Moro, France
8:30 Present and Future of Novel Deep Brain Stimulation Technologies in Parkinson's Disease
        Rob De Bie, Netherlands
9:00 Present and Future of Focused Ultrasound in Parkinson's Disease
        Raul Martinez, Spain

ESPC Liaison: Pablo Mir, Spain

At the conclusion of this session, participants should be better able to:
1. Define the benefits of traditional deep brain stimulation in Parkinson’s disease
2. Interpret the impact of novel hardware and software solutions for deep brain stimulation in Parkinson’s disease patients
3. Identify the targets and best Parkinson’s disease candidates for treatment with focused ultrasound

Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

3102 ES Summit Poster Hot Topics

9:30 – 10:00
Chairs: Bastiaan R. Bloem, Netherlands
        Angelo Antonini, Italy

3103 Plenary Session

Towards Personalized Management of Parkinson's Disease
10:30 – 12:30
Chairs: Alfredo Berardelli, Italy
        Claudia Trenkwalder, Germany

10:30 No Two Patients are the Same
        Rejko Krueger, Luxembourg
11:00 Gender Issues in Parkinson's Disease Care and Research
        Paolo Barone, Italy
11:30 The Need for New Trial Designs
        Jean-Christophe Corvol, France
12:00 Personalized Parkinson's Disease Programs in Daily Clinical Practice
        Kailash Bhatia, United Kingdom

ESPC Liaison: Daniela Berg, Germany

At the conclusion of this session, participants should be better able to:
1. Evaluate the variation in clinical presentation of symptoms spectrum of Parkinson’s disease
2. Analyze the substantial differences between men and women living with Parkinson’s disease in both daily care and clinical trials
3. Identify the need to for new trial designs in this time and era of personalized medicine
4. Recognize how personalized management strategies can and should be applied in everyday clinical practice

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees